Centessa finalizes advisory and separation pacts with former CEO Saha

Centessa Pharmaceuticals plc

Saurabh Saha stepped down as CEO on Jan 1, 2026; advisory agreement signed Feb 9, 2026.
Advisory fee of $376/hour for initial six-month term, renewable automatically.
Separation provides vesting of equity through Feb 2, 2026; later equity forfeited.
Subject to Compensation Committee approval, Saha eligible for 100% of 2025 target bonus.
Vested equity exercise window extends to three months after advisory agreement ends.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.